Compare FMBH & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMBH | KALV |
|---|---|---|
| Founded | 1865 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1995 | 2014 |
| Metric | FMBH | KALV |
|---|---|---|
| Price | $42.71 | $26.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $43.40 | $32.60 |
| AVG Volume (30 Days) | 65.2K | ★ 4.3M |
| Earning Date | 04-29-2026 | 07-09-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ 16.06 | N/A |
| EPS | ★ 1.06 | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | $9.30 | $185.42 |
| Revenue Next Year | $6.66 | $59.23 |
| P/E Ratio | $40.40 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $33.67 | $9.83 |
| 52 Week High | $44.85 | $26.85 |
| Indicator | FMBH | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 75.30 |
| Support Level | $42.36 | $14.66 |
| Resistance Level | $42.85 | N/A |
| Average True Range (ATR) | 0.94 | 0.39 |
| MACD | -0.11 | 0.25 |
| Stochastic Oscillator | 48.18 | 98.72 |
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.